Statins are currently the most widely used drug class for the management of dyslipidemia. Their benefits for both primary and secondary prevention of cardiovascular morbidity and mortality are well established. With the increasingly widespread use of statins, questions have been raised about a potential link between statin use and new onset type II diabetes. Evidence for this association was further strengthened by a recent study using data from the Women's Health Initiative (WHI), which reported an increased risk of diabetes with statin use in postmenopausal women. This article will provide an overview of the study findings and discuss implications for clinical practice.
Get full access to this article
View all access options for this article.
References
1.
RogerV.L.GoA.S.Lloyd-JonesD.M.American Heart Association. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation.2012; 125(1): e2–e220.
2.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation.2002; 106(25): 3143–3421.
3.
LewisS.J.Lipid-lowering therapy: Who can benefit?Vasc Health Risk Manage.2011; 7: 525–534.
4.
CulverA.L.OckeneI.S.BalasubramanianR.Statin use and risk of diabetes mellitus in postmenopausal women in the women's health initiative. Arch Intern Med.2012; 172: 144–152.
5.
FreemanD.J.NorrieJ.SattarN.Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation.2001; 103: 357–362.
6.
CollinsR.ArmitageJ.ParishS.MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet.2003; 361: 2005–2016.
7.
SeverP.S.DahlofB.PoulterN.R.Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than- average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet.2003; 361: 1149–1158.
8.
KjekshusJ.ApetreiE.BarriosV.Rosuvastatin in older patients with systolic heart failure. N Engl J Med.2007; 357: 2248–2261.
9.
RidkerP.M.DanielsonE.FonsecaF.A.Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med.2008; 359: 2195–2207.
10.
SattarN.PreissD.MurrayH.M.Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet.2010; 375: 735–742.
11.
WatersD.D.HoJ.E.DeMiccoD.A.Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol.2011; 57: 1535–1545.
12.
LaRosaJ.C.GrundyS.M.WatersD.D.Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med.2005; 352: 1425–1435.
13.
PedersenT.R.FaergemanO.KasteleinJ.J.High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study – a randomized controlled trial. JAMA.2005; 294: 2437–2445.
14.
CannonC.P.BraunwaldE.McCabeC.H.Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med.2004; 350: 1495–1504.
15.
de LemosJ.A.BlazingM.A.WiviottS.D.Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA.2004; 292: 1307–1316.
16.
ArmitageJ.BowmanL.WallendszusK.Intensive lowering of LDL cholesterol with 80mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet.2010; 376: 1658–1669.
17.
PreissD.SeshasaiS.R.WelshP.Risk of incident diabetes with intensive dose compared with moderate-dose statin therapy: a meta-analysis. JAMA.2011; 305: 2556–2564.
18.
SukhijaR.PrayagaS.MarashdehM.Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. J Investig Med.2009; 57: 495–499.
19.
BakerW.L.TalatiR.WhiteC.M.ColemanC.I.Differing effect of statins on insulin sensitivity in nondiabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract.2010; 87: 98–107.
KearneyP.M.BlackwellL.CollinsR.Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet.2008; 371: 117–125.
23.
MoraS.GlynnR.J.HsiaJ.Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation.2010; 121: 1069–1077.
